2020 Fatigue Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Fatigue pipeline report presents a comprehensive overview of the research and development of Fatigue drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, one drug in Phase 1, and three drugs in Phase 2
As of February 2020, the Fatigue pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Fatigue treatment. Diverse types of targeted therapies are being explored through clinical trials including thyrotropin releasing hormone receptor (TRHR) agonist; Adrenergic uptake inhibitor; dopamine transporter inhibitor; Dopamine uptake inhibitor; ghrelin receptor agonist; noradrenaline transporter inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Fatigue drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Fatigue pipeline drugs profiled in the report include- MS CTDP-001, anamorelin (ONO-7643), KPAX002, MRZ-9547, MCT-125(lofepramine + phenylalanine), PLS-4, Tissue based Chronic Pain and Fatigue
As of February 2020, the Fatigue pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Fatigue treatment. Diverse types of targeted therapies are being explored through clinical trials including thyrotropin releasing hormone receptor (TRHR) agonist; Adrenergic uptake inhibitor; dopamine transporter inhibitor; Dopamine uptake inhibitor; ghrelin receptor agonist; noradrenaline transporter inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Fatigue drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Fatigue development
- Fatigue pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Fatigue pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Fatigue pipeline candidates included
- Business overview and snapshot of all companies involved in Fatigue pipeline are included
- Latest market and pipeline developments are provided in the report
Fatigue pipeline drugs profiled in the report include- MS CTDP-001, anamorelin (ONO-7643), KPAX002, MRZ-9547, MCT-125(lofepramine + phenylalanine), PLS-4, Tissue based Chronic Pain and Fatigue
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Fatigue Condition
2.3 Fatigue Pipeline Snapshot, 2020
2.4 Companies investing in Fatigue pipeline therapeutics
2.5 Phase wise Fatigue Pipeline Candidates
2.6 Most Researched Mechanism of Action of Fatigue Pipeline Products
2.7 Route of Administration of Fatigue Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Chronos Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.2 Helsinn Group Overview, Contacts and ASD Pipeline Drugs
3.3 K-Pax Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Merz Pharma GmbH & Co KgaA Overview, Contacts and ASD Pipeline Drugs
3.5 MultiCell Technologies Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Primetime Life Sciences LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Resolys Bio Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 MS CTDP-001 Drug Details
4.1.1 MS CTDP-001 Current Status
4.1.2 MS CTDP-001 Drug Overview
4.1.3 MS CTDP-001 Mechanism of Action
4.1.4 MS CTDP-001 Licensing/Collaboration Companies
4.1.5 MS CTDP-001 Clinical Trials
4.2 anamorelin (ONO-7643) Drug Details
4.2.1 anamorelin (ONO-7643) Current Status
4.2.2 anamorelin (ONO-7643) Drug Overview
4.2.3 anamorelin (ONO-7643) Mechanism of Action
4.2.4 anamorelin (ONO-7643) Licensing/Collaboration Companies
4.2.5 anamorelin (ONO-7643) Clinical Trials
4.3 KPAX002 Drug Details
4.3.1 KPAX002 Current Status
4.3.2 KPAX002 Drug Overview
4.3.3 KPAX002 Mechanism of Action
4.3.4 KPAX002 Licensing/Collaboration Companies
4.3.5 KPAX002 Clinical Trials
4.4 MRZ-9547 Drug Details
4.4.1 MRZ-9547 Current Status
4.4.2 MRZ-9547 Drug Overview
4.4.3 MRZ-9547 Mechanism of Action
4.4.4 MRZ-9547 Licensing/Collaboration Companies
4.4.5 MRZ-9547 Clinical Trials
4.5 MCT-125(lofepramine + phenylalanine) Drug Details
4.5.1 MCT-125(lofepramine + phenylalanine) Current Status
4.5.2 MCT-125(lofepramine + phenylalanine) Drug Overview
4.5.3 MCT-125(lofepramine + phenylalanine) Mechanism of Action
4.5.4 MCT-125(lofepramine + phenylalanine) Licensing/Collaboration Companies
4.5.5 MCT-125(lofepramine + phenylalanine) Clinical Trials
4.6 PLS-4 Drug Details
4.6.1 PLS-4 Current Status
4.6.2 PLS-4 Drug Overview
4.6.3 PLS-4 Mechanism of Action
4.6.4 PLS-4 Licensing/Collaboration Companies
4.6.5 PLS-4 Clinical Trials
4.7 Tissue based Chronic Pain and Fatigue Drug Details
4.7.1 Tissue based Chronic Pain and Fatigue Current Status
4.7.2 Tissue based Chronic Pain and Fatigue Drug Overview
4.7.3 Tissue based Chronic Pain and Fatigue Mechanism of Action
4.7.4 Tissue based Chronic Pain and Fatigue Licensing/Collaboration Companies
4.7.5 Tissue based Chronic Pain and Fatigue Clinical Trials
5. LATEST FATIGUE PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Fatigue Condition
2.3 Fatigue Pipeline Snapshot, 2020
2.4 Companies investing in Fatigue pipeline therapeutics
2.5 Phase wise Fatigue Pipeline Candidates
2.6 Most Researched Mechanism of Action of Fatigue Pipeline Products
2.7 Route of Administration of Fatigue Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Chronos Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.2 Helsinn Group Overview, Contacts and ASD Pipeline Drugs
3.3 K-Pax Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Merz Pharma GmbH & Co KgaA Overview, Contacts and ASD Pipeline Drugs
3.5 MultiCell Technologies Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Primetime Life Sciences LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Resolys Bio Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 MS CTDP-001 Drug Details
4.1.1 MS CTDP-001 Current Status
4.1.2 MS CTDP-001 Drug Overview
4.1.3 MS CTDP-001 Mechanism of Action
4.1.4 MS CTDP-001 Licensing/Collaboration Companies
4.1.5 MS CTDP-001 Clinical Trials
4.2 anamorelin (ONO-7643) Drug Details
4.2.1 anamorelin (ONO-7643) Current Status
4.2.2 anamorelin (ONO-7643) Drug Overview
4.2.3 anamorelin (ONO-7643) Mechanism of Action
4.2.4 anamorelin (ONO-7643) Licensing/Collaboration Companies
4.2.5 anamorelin (ONO-7643) Clinical Trials
4.3 KPAX002 Drug Details
4.3.1 KPAX002 Current Status
4.3.2 KPAX002 Drug Overview
4.3.3 KPAX002 Mechanism of Action
4.3.4 KPAX002 Licensing/Collaboration Companies
4.3.5 KPAX002 Clinical Trials
4.4 MRZ-9547 Drug Details
4.4.1 MRZ-9547 Current Status
4.4.2 MRZ-9547 Drug Overview
4.4.3 MRZ-9547 Mechanism of Action
4.4.4 MRZ-9547 Licensing/Collaboration Companies
4.4.5 MRZ-9547 Clinical Trials
4.5 MCT-125(lofepramine + phenylalanine) Drug Details
4.5.1 MCT-125(lofepramine + phenylalanine) Current Status
4.5.2 MCT-125(lofepramine + phenylalanine) Drug Overview
4.5.3 MCT-125(lofepramine + phenylalanine) Mechanism of Action
4.5.4 MCT-125(lofepramine + phenylalanine) Licensing/Collaboration Companies
4.5.5 MCT-125(lofepramine + phenylalanine) Clinical Trials
4.6 PLS-4 Drug Details
4.6.1 PLS-4 Current Status
4.6.2 PLS-4 Drug Overview
4.6.3 PLS-4 Mechanism of Action
4.6.4 PLS-4 Licensing/Collaboration Companies
4.6.5 PLS-4 Clinical Trials
4.7 Tissue based Chronic Pain and Fatigue Drug Details
4.7.1 Tissue based Chronic Pain and Fatigue Current Status
4.7.2 Tissue based Chronic Pain and Fatigue Drug Overview
4.7.3 Tissue based Chronic Pain and Fatigue Mechanism of Action
4.7.4 Tissue based Chronic Pain and Fatigue Licensing/Collaboration Companies
4.7.5 Tissue based Chronic Pain and Fatigue Clinical Trials
5. LATEST FATIGUE PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
